News

The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and

The agreement includes Metabolex's two clinical compounds, metaglidasen and MBX-2044, and additional follow-on compounds for which Ortho-McNeil, a Johnson & Johnson company, has received an exclusive license for

Having obtained positive results with Anturol, an oxybutynin gel product, in a phase II clinical study, Antares now plans to initiate a phase III clinical program in patients

The companies have not disclosed details of the specific compounds involved in the supply but have said that sales of the products exceeded $130 million in 2005. Lannett,

The T315I point mutation is attracting significant attention globally as T315I expressing cells are resistant to Novartis’ tyrosine kinase inhibitor, Gleevec, meaning chronic myeloid leukemia (CML) patients who

Preclinical studies of the formulation have been completed in preparation for initiating studies to determine feasibility in human subjects. Under the terms of the agreement, Nastech will receive

The agreement, signed in July 2004, provided Schering AG with exclusive commercialization rights to Alprox-TD in Europe, Russia, the Middle East, South Africa, Australia and New Zealand. NexMed

According to the company, preliminary analyses of information from the 13-week toxicology studies in animals have revealed various new observations which appear consistent with intense immune stimulation in

In the alliance, Medarex intends to use its UltiMab technology to create antibodies to targets provided by Euroscreen. Under the terms of the agreement, Euroscreen has granted Medarex